Anglo American PLC (LON:AAL) Investors: Liberum Capital Reconfirms “Sell” Rating, Sees GBX 800.00/Share; Arrowhead Pharmaceuticals (ARWR) SI Decreased By 15.98%

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) had a decrease of 15.98% in short interest. ARWR’s SI was 3.76M shares in March as released by FINRA. Its down 15.98% from 4.48M shares previously. With 2.23M avg volume, 2 days are for Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)’s short sellers to cover ARWR’s short positions. The SI to Arrowhead Pharmaceuticals Inc’s float is 5.51%. The stock increased 9.31% or $0.62 during the last trading session, reaching $7.28. About 3.76M shares traded or 101.97% up from the average. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has declined 67.27% since March 6, 2017 and is downtrending. It has underperformed by 83.97% the S&P500.

Stock analysts at Liberum Capital have GBX 800.00 TP on Anglo American PLC (LON:AAL). Liberum Capital’s TP means a potential downside of -52.41% from the company’s previous close. The rating was revealed in an analyst note on 6 March.

Among 27 analysts covering Anglo American PLC (LON:AAL), 12 have Buy rating, 5 Sell and 10 Hold. Therefore 44% are positive. Anglo American PLC has GBX 2200 highest and GBX 152 lowest target. GBX 1292.19’s average target is -25.92% below currents GBX 1744.2 stock price. Anglo American PLC had 491 analyst reports since July 22, 2015 according to SRatingsIntel. The firm earned “Underweight” rating on Thursday, June 23 by Barclays Capital. The firm has “Hold” rating given on Friday, March 17 by Deutsche Bank. The firm earned “Underperform” rating on Friday, July 15 by Jefferies. The company was maintained on Wednesday, November 4 by Jefferies. The company was maintained on Monday, June 5 by JP Morgan. On Tuesday, February 27 the stock rating was maintained by Credit Suisse with “Neutral”. The firm has “Neutral” rating by BNP Paribas given on Wednesday, December 16. The stock has “Hold” rating by Canaccord Genuity on Tuesday, February 16. As per Tuesday, September 5, the company rating was maintained by JP Morgan. The firm earned “Overweight” rating on Monday, August 22 by JP Morgan.

The stock increased 3.01% or GBX 51 during the last trading session, reaching GBX 1744.2. About 1.34 million shares traded. Anglo American plc (LON:AAL) has 0.00% since March 6, 2017 and is . It has underperformed by 16.70% the S&P500.

Investors sentiment decreased to 0.66 in Q3 2017. Its down 0.25, from 0.91 in 2017Q2. It worsened, as 53 investors sold Anglo American plc shares while 210 reduced holdings. 55 funds opened positions while 118 raised stakes. 380.49 million shares or 2.17% less from 388.91 million shares in 2017Q2 were reported. Wells Fargo And Mn has 1.07 million shares. Landscape Capital Management Ltd accumulated 7,429 shares. Camarda Limited Co stated it has 0.01% of its portfolio in Anglo American plc (LON:AAL). Commonwealth Of Pennsylvania Public School Empls Retrmt reported 0.02% in Anglo American plc (LON:AAL). Fincl Mngmt Incorporated reported 0.29% stake. Teewinot Advisers Limited Com holds 1.1% or 51,500 shares. Asset Management One Com Ltd owns 194,535 shares for 0.02% of their portfolio. 1832 Asset Limited Partnership owns 2,266 shares for 0% of their portfolio. Quantitative Systematic Strategies Lc has 0.14% invested in Anglo American plc (LON:AAL). Psagot House reported 1,800 shares or 0% of all its holdings. Valley Advisers has invested 0.01% in Anglo American plc (LON:AAL). Leuthold Group Limited Liability Co holds 155,846 shares or 0.75% of its portfolio. Aperio Grp Ltd Liability Co owns 133,771 shares or 0.04% of their US portfolio. Us Bankshares De reported 8,203 shares. 103,812 were reported by Ing Groep Nv.

Analysts await Anglo American plc (LON:AAL) to report earnings on April, 26. They expect $0.53 EPS, down 13.11% or $0.08 from last year’s $0.61 per share. AAL’s profit will be $7.42 million for 822.74 P/E if the $0.53 EPS becomes a reality. After $0.95 actual EPS reported by Anglo American plc for the previous quarter, Wall Street now forecasts -44.21% negative EPS growth.

Anglo American plc, together with its subsidiaries, engages in exploring, mining, processing, and smelting bulk commodities, base metals and minerals, and precious metals and minerals worldwide. The company has market cap of 24.42 billion GBP. The firm explores for iron ore, manganese ore, and alloys; metallurgical and thermal coal; copper; nickel; niobium; phosphates; platinum group metals; and rough and polished diamonds. It has a 7.12 P/E ratio.

Since September 14, 2017, it had 0 insider purchases, and 4 selling transactions for $4.24 million activity. ROBINSON RAY M also sold $162,523 worth of Anglo American plc (LON:AAL) on Thursday, September 14. HART MATTHEW J also sold $1.83M worth of Anglo American plc (LON:AAL) shares. KERR DEREK J sold 39,662 shares worth $2.09M. On Monday, January 29 the insider KRAEMER RICHARD C sold $158,139.

Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. The company has market cap of $631.81 million. The Company’s pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. It currently has negative earnings. The firm also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma.

Among 8 analysts covering Arrowhead Research Corp (NASDAQ:ARWR), 4 have Buy rating, 0 Sell and 4 Hold. Therefore 50% are positive. Arrowhead Research Corp had 24 analyst reports since August 5, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) rating on Monday, September 25. Cantor Fitzgerald has “Hold” rating and $2.0 target. Piper Jaffray maintained the stock with “Overweight” rating in Friday, September 25 report. The firm has “Buy” rating given on Thursday, November 10 by Chardan Capital Markets. The rating was maintained by Jefferies on Monday, June 26 with “Hold”. The stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has “Neutral” rating given on Monday, February 12 by B. Riley & Co. The company was maintained on Monday, February 12 by Cantor Fitzgerald. The stock has “Hold” rating by Jefferies on Thursday, August 3. As per Thursday, May 19, the company rating was initiated by Chardan Capital Markets. The stock has “Hold” rating by Cantor Fitzgerald on Wednesday, November 30. The company was maintained on Thursday, September 14 by Piper Jaffray.